quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 14, 2026

South Korea Data Center Market Investment Analysis Report 2026-2031: Coverage of 58 Existing Facilities, 26 Upcoming Facilities, and 16+ Locations

View original at finance.yahoo.com
South Korea Data Center Market Investment Analysis Report 2026-2031: Coverage of 58 Existing Facilities, 26 Upcoming Facilities, and 16+ Locations Company Logo The South Korea Data Center Market is poised for robust growth, expected to propel from USD 5.04 billion in 2025 to USD 16.23 billion by 2031 at a CAGR of 21.52…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The South Korea Data Center Market was valued at USD 5.04 Billion in 2025, and is projected to reach USD 16.23 Billion by 2031, rising at a CAGR of 21.52%

    80% confidence

  • The cloud market in South Korea is expected to continue experiencing significant growth in the future

    80% confidence

  • South Korea consists of approximately 58 operational colocation data centers, of which around 32 facilities are in Seoul alone

    80% confidence

  • The average cost of developing a data center in South Korea ranges between $10-$11 million per MW, which is comparatively lower than several APAC nations like Singapore, Australia, Japan, and others

    80% confidence

  • Most of these facilities have been designed to meet the Tier III standards of the Uptime Institute

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
South Korea Data Center Market Investment Analysis Report 2026-2031: Coverage of 58 Existing Facilities, 26 Upcoming Facilities, and 16+ Locations — Source | Via News | pt.VIA.NEWS